Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NetraMark Holdings ( (TSE:AIAI) ) has provided an update.
NetraMark Holdings Inc. has signed four new contracts with a leading global pharmaceutical company to enhance clinical trial insights using their proprietary NetraAI platform. These agreements aim to improve the understanding of complex patient populations by identifying subpopulations that drive treatment and placebo responses, aligning with FDA expectations for explainable AI methods. This expansion of collaboration reflects confidence in NetraMark’s technology and its potential impact on clinical trial success.
More about NetraMark Holdings
NetraMark Holdings Inc. is a leader in the development of Generative Artificial Intelligence and Machine Learning solutions for the pharmaceutical industry. The company specializes in AI-powered precision analytics to transform clinical trials, utilizing a unique topology-based algorithm to parse patient data into subsets for improved drug sensitivity and treatment efficacy analysis.
Average Trading Volume: 42,882
Technical Sentiment Signal: Buy
Current Market Cap: C$98.73M
For detailed information about AIAI stock, go to TipRanks’ Stock Analysis page.